BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Episodes
In this episode, you'll be listening to Akshay Rai, principal, Healthcare & Biotech Investments at Premji Invest and Viswa Colluru, CEO and founder, Enveda. They discuss how AI platforms must now prove themselves through data, focused pipelines and clinical readouts and that promises of faster, cheaper drug discovery are not enough to entice strong investor engagement.
Host
Jennifer Smith-Parker, Director of Insights, BioSpace
...
Biopharma’s weight loss warriors have led the news this week, with Structure Therapeutics and Rhythm Pharmaceuticals announcing new data. Structure delivered a “competitive profile” for its investigational GLP-1 pill compared to Eli Lilly’s orforglipron and Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote to investors, after the candidate elicited 16.3% weight loss after 44 weeks in a Phase 2 trial. Rhythm was not as successfu...
In this episode of Denatured, you'll listen to Oxana Iliach, senior director of regulatory strategy at Certara and Vera Pomerantseva, director of product management for risk-based quality management at eClinical Solutions. We speak about how the FDA's latest decision to have one, rather than two pivotal studies, for new drug applications raises the bar for data collection and risk-based management.
Host
Jennifer C. Smith-Parker, Di...
After Friday’s news that Center for Biologics Evaluation & Research Chief Vinay Prasad will leave the FDA—again—at the end of April, stocks for several rare disease drug developers popped. UniQure, in particular, was up 51% in premarket trading on Monday. Prasad in a meeting last Thursday with select journalists called the biotech’s Huntington’s treatment AMT-130 a “failed” therapy, according to STAT News. Shares of Replimune a...
Stylus Medicine CEO Emile Nuwaysir and Chief Scientific Officer Jason Fontenot speak with BioSpace about the biotech's work on next-generation genetic medicines—and why they think it’s the perfect time to be in the cell therapy game.
Stylus Medicine is featured in BioSpace's list, the top startups to watch in the U.S.
Host
Annalee Armstrong, Senior Editor, BioSpace
Guests
Emile Nuwaysir, CEO, Stylus Medicine
Jason Fontenot, Chief Scien...
In this Denatured episode, Jennifer C. Smith-Parker speaks to Ram May-Ron, managing partner at FreeMind Group, and Ravi Kiron, managing director at Biopharma Strategy Advisors. We'll discuss how best to tailor an investment approach of both nondilutive funding and family offices to overcome the drug development valley of death.
Host
Jennifer Smith-Parker, Director of Insights, BioSpace
Guests
Ram May-Ron, Managing Partner, FreeMind ...
The FDA is dominating the headlines once again thisweek.
Days after FDA Commissioner Marty Makary appeared to question uniQure’s gene therapy candidate for Huntington’s disease, the company revealed that the agency will require it to conduct a randomized, double-blind, sham surgery–controlled Phase 3 study. The FDA also published anothercomplete response letter (CRL), this one for REGENXBIO’s gene therapy for Hunter syndrome. The ...
In this episode, you'll be listening to Indu Navar, CEO and founder of EverythingALS and Dr. Olga Uspenskaya, chief medical officer at VectorY Therapeutics. We'll be speaking about patient-pharma collaborations accelerating trials and hope, advances in ALS biology understanding and biomarker-driven endpoints.
Host
Jennifer Smith-Parker, Director of Insights, BioSpace
Guests
Indu Navar, CEO and Founder, EverythingALS
Eli Lilly notches another win over Novo Nordisk, as Zepbound bests CagriSema in a head-to-head trial sponsored by Novo; The FDA kicked off Rare Disease Week, providing draft guidance on its new plausible mechanism pathway, while a bipartisan senate hearing on Thursday will focus on the authorization process for rare conditions; Another leadership change shakes up CDC; and Gilead acquires CAR T partner Arcellx for nearly $8 billion....
Corsera Health’s Chief Operating Officer Rena Denoncourt and CFO Meredith Kaya speak with BioSpace about the biotech’s mission and vision for the next generation of cardiovascular care in this special bonus episode.
Corsera Health is featured in BioSpace's NextGen: Class of 2026 list, the top startups to watch in the U.S.
Host
Annalee Armstrong, Senior Editor, BioSpace
Guests
Rena Denoncourt, Chief Operating Officer, Corsera Health
In this episode, you'll be listening to Jane Hughes, President of R&D and Co Founder of Verdiva Bio, and Jon Rees, CEO and cofounder of MitoRx Therapeutics. We'll discuss next-generation obesity solutions tackling GLP-1's muscle loss and adherence challenges, through innovative muscle preservation, oral administration and combination therapy.
Host
Jennifer Smith-Parker, Director of Insights, BioSpace
Guests
Jane Hughes, President o...
Last week, the FDA declined to review Moderna’s mRNA-based flu vaccine, with Center for Biologics Evaluation and Research Director Vinay Prasad himself signing the refuse-to-file (RTF) letter. Prasad said Moderna’s comparator group “does notreflect the best-available standard of care,” while Moderna pushed back, saying CBER had previously found a standard-dose flu shot to be an “acceptable” comparator. Despite the shocking turn of ...
Last year, the FDA announced it would be phasingout animal testing requirements for some therapies. The NIHfollowed suit. According to Thomas Hartung, professor and chair at Johns Hopkins Bloomberg School of Public Health, these policy shifts are an “overdue adaptation to scientific progress.”
In this special edition of The Weekly, Hartung discusses howartificial intelligence (AI) and various non-animal models such as human organoi...
In this episode of Denatured, Jennifer C. Smith-Parker speaks with Dr. Rob Monroe, Vice President and Chief Scientific Officer of Oncology at Danaher Corporation and Chief Medical Officer at Leica Biosystems, and Jennifer Fakish, Vice President and Franchise Head of Oncology at Danaher Corporation.
We'll be discussing how antibody drug conjugates (ADCs) are transforming cancer care and with AI-powered pathology, doctors can now mea...
Last Thursday, Hims & Hers launched a compounded versionof Novo’s oral Wegovy, approved just before Christmas and launched in early January. Novo was, not surprisingly, none too pleased. FDA Commissioner Marty Makary denounced“illegal copycat drugs” in an X post the same day without naming Hims, which then said it would notsell the oral weight loss drug. Novo sued the consumer healthcare company for patent infringement, seeking...
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklud, CEO of Circio and Jacob Becraft, CO-founder and CEO of Strand Therapeutics.
Since the mRNA vaccine breakthroughs of the COVID-19 era, attention has turned to what's next for programmable medicines. While first- generation mRNA prove the power of transient genetic instruction, its instability, immune reactivity, and short-lived expression have limit...
Pfizer reported the first data from its new obesity pipeline, picked up in the nearly $10 billion acquisition of Metsera last fall. While BMO Capital Markets said in a Tuesday note that the data “look competitive,” analysts clamored for more details on Pfizer’s earnings call the same morning—and were left wanting more. Meawhile, Merck batted away accusations of “modest growth” from analysts on its own earnings call, as CEO Robert D...
In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW’s Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential; why oncology, obesity, psychedelics, and neuroscience are attracting fresh capital; and how “alpha stacking” shapes their investment edge in an age of chronic uncertainty. They cover topics discussed in RTW's new book, "Innovation is the Best Medicine."
Hosts
Roche made the biggest splash this week so far, announcing on Tuesday that GLP-1/GIP injectable CT-388 led to 22.5%weight loss in a Phase II trial. These numbers appear to put CT-388, which Roche acquired in its $2.7 billion Carmot buy, in line with Eli Lilly’s Zepbound, according to William Blair analysts. Roche plans to start a Phase III study of CT-388 in the first half of this year and is also pairing the drug with a therapy fr...
In this episode of Denatured, BioSpace editorial team members, Senior Editor, Annalee Armstrong, and News Editor, Dan Samorodnitsky, discuss their post-JPM takeaways and 2026 forecasts after speaking to a range of pharma and biotech executives and investors last week.
Hosts
Jennifer Smith-Parker, Director of Insights, BioSpace
Guests
Annalee Armstrong, Senior Editor, BioSpace
Dan Samorodnitsky, News Editor, BioSpace
Disclaimer: The ...
Popular Podcasts
How do the smartest marketers and business entrepreneurs cut through the noise? And how do they manage to do it again and again? It's a combination of math—the strategy and analytics—and magic, the creative spark. Join iHeartMedia Chairman and CEO Bob Pittman as he analyzes the Math and Magic of marketing—sitting down with today's most gifted disruptors and compelling storytellers.
CBS Sports’ official college basketball podcast is the most entertaining and informative of its kind. Gary Parrish and Matt Norlander bring the sport into your ears at least three times per week with commentary, reporting, insider information and statistical analysis throughout college basketball all year long.
The Questlove Show builds on the award-winning Questlove Supreme podcast, bringing listeners into intimate, one-on-one conversations with peers, influences, and friends. Hosted by Ahmir “Questlove” Thompson, each episode uncovers the unexpected — from morning rituals and hidden talents to the art and experiences that shaped a guest’s journey. Sometimes playful, sometimes profound, always curious, QLS offers rare insight into leaders in music, film, television, comedy, literature, mental health, and beyond. It’s a fresh, unpredictable spin from a trusted source — a place where randomness is encouraged, tangents are welcomed, and conversations are anything but ordinary.
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
The Dan Bongino Show delivers no-nonsense analysis of the day’s most important political and cultural stories. Hosted by the former Deputy Director of the FBI, former Secret Service agent, NYPD officer, and bestselling author Dan Bongino, the show cuts through media spin with facts, accountability, and unapologetic conviction. Whether it’s exposing government overreach, defending constitutional freedoms, or connecting the dots the mainstream media ignores, The Dan Bongino Show provides in-depth analysis of the issues shaping America today. Each episode features sharp commentary, deep dives into breaking news, and behind-the-scenes insight you won’t hear anywhere else. Apple: https://podcasts.apple.com/us/podcast/the-dan-bongino-show/id965293227?mt=2 Spotify: https://open.spotify.com/show/4sftHO603JaFqpuQBEZReL?si=PBlx46DyS5KxCuCXMOrQvw Rumble: https://rumble.com/c/bongino?e9s=src_v1_sa%2Csrc_v4_sa_o